The societal impact of natalizumab treatment in the Italian relapsing-remitting multiple sclerosis clinical practice: The tysabri® pharmacoeconomics (TYPE) study

Authors
Category Primary study
JournalValue in Health
Year 2016
This article has no abstract
Epistemonikos ID: 432a498f836734b0fa9c5a405883a7f8536dc276
First added on: Feb 08, 2025